NASDAQ: RZLTRezolute Inc Stock
$4.57+0.24 (+5.54%)
Updated Jun 16, 2026
RZLT Price
$4.57
Fair Value Price
$1.22
Market Cap
$440.06M
52 Week Low
$1.07
52 Week High
$11.46
P/E
-5.57x
P/B
3.77x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$81.49M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$73M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RZLT Overview
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RZLT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RZLT
Ranked#227 of 462
Ranked#227 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important RZLT news, forecast changes, insider trades & much more!
RZLT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RZLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RZLT ($4.57) is overvalued by 275.51% relative to our estimate of its Fair Value price of $1.22 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RZLT ($4.57) is not significantly undervalued (275.51%) relative to our estimate of its Fair Value price of $1.22 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RZLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RZLT due diligence checks available for Premium users.
Valuation
RZLT fair value
Fair Value of RZLT stock based on Discounted Cash Flow (DCF)
Price
$4.57
Fair Value
$1.22
Overvalued by
275.51%
RZLT ($4.57) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RZLT ($4.57) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RZLT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RZLT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.57x
Industry
16.03x
Market
13.25x
RZLT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.77x
Industry
4.86x
RZLT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RZLT's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.2M
Profit Margin
0%
RZLT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$125.5M
Liabilities
$8.6M
Debt to equity
0.07
RZLT's short-term assets ($122.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RZLT's short-term assets ($122.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RZLT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RZLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.7M
Investing
$12.3M
Financing
$747.0k
RZLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RZLT vs Biotech Stocks
Rezolute Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.